Vaxcyte, Inc.
PCVX
USReal-Time PriceVaxcyte, Inc. (PCVX) Stock News
The latest Vaxcyte, Inc. (PCVX) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.
Vaxcyte’s VAX-31 Phase 3 Win Raises the Competitive Bar
VAX-31 met its pivotal adult immunogenicity goals, strengthening Vaxcyte’s case for broader pneumococcal coverage while execution risks remain.
Vaxcyte Phase 3 Data Strengthen VAX-31, but Two Trials Still Matter
VAX-31 met all prespecified OPUS-1 primary endpoints and broadened serotype coverage, supporting a best-in-class thesis while regulatory and manufacturing risk remain.
VAX-31 Creates a Longer-Term Competitive Risk for Pfizer Prevnar
Vaxcyte matched established pneumococcal vaccines across shared serotypes and added broader coverage, but Pfizer has time to defend Prevnar before a possible 2028 filing.
Vaxcyte Uses Phase 3 Strength to Raise $1 Billion for the Next Stage
Vaxcyte priced $500 million of equity and $500 million of convertibles after OPUS-1, trading dilution for a longer runway into additional trials and launch preparation.